The Business of Healthcare InnovationLawton Robert Burns The Business of Healthcare Innovation is a wide-ranging analysis of business trends in the manufacturing segment of the healthcare industry. It provides a thorough overview and introduction to the innovative sectors fueling improvements in healthcare: pharmaceuticals, biotechnology, platform technology, medical devices and information technology. For each sector, the book examines the basis and trends in scientific innovation, the business and revenue models pursued to commercialize that innovation, the regulatory constraints within which each sector must operate and the growing issues posed by more activist payers and consumers. Specific topics include market structure and competition, the economics and rationale of product development, pricing, sales and marketing, contract negotiations with buyers, alliances versus mergers, business strategies and prospects for growth. Written by professors of the Wharton School and industry executives, the book shows why healthcare sectors are such an important source of growth in any nation's economy. |
Contents
rebooted and reinvigorated 32 | |
Pharmaceutical strategy and the evolving role of merger and acquisition 116 | |
therapeutics 194 | |
implications | |
Other editions - View all
Common terms and phrases
Accessed Feb Accessed Jan Accessed Sept acquisition Amgen antibodies approval AstraZeneca Available benefits billion biologics Biotech biotechnology companies biotechnology firms biotechnology sector Burrill and Company business models challenges clinical trials company’s convergence cost CPOE created deals decade defibrillators disease drug development drug discovery economic Ernst and Young field Figure financial financing find first five funding gene gene therapy Genentech genomics global growth Health healthcare hospital human Ibid impact implants increased industry innovation integration investment investors large pharmaceutical manufacturing medical device medical products medicine Medtronic Merck merger molecules monoclonal antibodies NMEs Novartis organizations outsourcing patients payers percent Pfizer Pharma pharmaceutical companies pharmaceutical firms pharmaceutical sector phase physicians pipeline platform potential profit programs protein proteomics regulatory revenues Sanofi-Aventis Sciences scientific significant Source specific spending stents strategy success target technological convergence therapeutic therapy tion value chain venture capital Vivo